Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Neoplasms 28Lung Neoplasms 24Neoplasm Metastasis 12Mesothelioma, Malignant 11Mesothelioma 10Colorectal Neoplasms 10Ovarian Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Melanoma 5Head and Neck Neoplasms 5Breast Neoplasms 5Adenocarcinoma of Lung 5Pancreatic Neoplasms 4Carcinoma 4Advanced Cancer 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Lymphoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Advanced Solid Tumors 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2

Interventions

Cyclophosphamide 11ruxolitinib 10fludarabine phosphate 9Tacrolimus 7Filgrastim 7fludarabine 6Decitabine 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Busulfan 5navitoclax 4Sirolimus 4Etoposide 4Azacitidine 4Specimen Handling 3Methylprednisolone 3Methotrexate 3Melphalan 3Cyclosporine 3Antilymphocyte Serum 3venetoclax 2thymoglobulin 2durvalumab 2Vorinostat 2Thiotepa 2Sunitinib 2Stem Cell Transplantation 2Radiotherapy 2Prednisone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Primary Myelofibrosis × Pemetrexed × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡